UNIMMAP MMS is one of the best investments that countries can make in their development – driving healthier communities and stronger economies.
Women and girls are disproportionately impacted by malnutrition, and their poor nutrition bears generational consequences for their families, communities, and their nation. MMS is a small but mighty intervention that can deliver gender-responsive transformational impact.
Women lose years of their lives to poor health and malnutrition, which affect their ability to be present and productive at home, in the workforce, and in their communities.
Poor nutrition in the early days of a child’s life can cause irreversible damage to their growing brain, affecting their ability to do well in school and earn a good living—and making it more difficult for a child and their family to rise out of poverty.
This makes MMS one of the most cost-effective nutrition interventions available to governments and partners. In 2023, MMS was named one of the 12 best investments in global development by the Copenhagen Consensus, a think tank composed of leading economists that specializes in identifying the most effective solutions for global development challenges.
UNIMMAP MMS can be produced at a little over $0.01 per dose, or $2-3 per woman per pregnancy, which means that it’s available at a similar price to iron-folic acid (IFA).
